<DOC>
	<DOC>NCT01720459</DOC>
	<brief_summary>The purpose of this study is to determine whether micronized trans-resveratrol improves clinical (excessive hair, menstrual cycle), endocrine (androgens)and metabolic (lipids, markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS).</brief_summary>
	<brief_title>Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>PCO Androgen Excess Society criteria: hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone &gt;70ng/dl) and/or oligomenorrhea (&lt;8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound Normal prolactin, TSH, 17OH progesterone No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly Age 1840 Use of oral contraceptives and/or other steroid hormones 3 months prior to the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>